Switch to:
Nivalis Therapeutics Inc (NAS:NVLS)
EV/EBIT
0.24 (As of Today)

EV/EBIT ratio is calculated as enterprise value divided by its Earnings Before Interest and Taxes (EBIT). As of today, Nivalis Therapeutics Inc's enterprise value is $-6.30 Mil. Nivalis Therapeutics Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2016 was $-26.52 Mil. Therefore, Nivalis Therapeutics Inc's EV/EBIT ratio for today is 0.24.

NVLS' s EV/EBIT Range Over the Past 10 Years
Min: 0   Max: 1.62
Current: 0.24

0
1.62

During the past 4 years, the highest EV/EBIT Ratio of Nivalis Therapeutics Inc was 1.62. The lowest was 0.00. And the median was 0.00.

NVLS's EV/EBIT is ranked higher than
94% of the 257 Companies
in the Global Biotechnology industry.

( Industry Median: 24.11 vs. NVLS: 0.24 )

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt). Nivalis Therapeutics Inc's enterprise value for the quarter that ended in Mar. 2016 was $-15.74 Mil. Nivalis Therapeutics Inc's earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2016 was $-26.52 Mil. Nivalis Therapeutics Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2016 was 168.43%.


Definition

Nivalis Therapeutics Inc's EV/EBIT for today is calculated as:

EV/EBIT=Enterprise Value (Today)/Earnings Before Interest and Taxes (EBIT) (TTM)
=-6.303/-26.517
=0.24

Nivalis Therapeutics Inc's current Enterprise Value is $-6.30 Mil.
Nivalis Therapeutics Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2016 was -5.852 (Jun. 2015 ) + -6.101 (Sep. 2015 ) + -6.63 (Dec. 2015 ) + -7.934 (Mar. 2016 ) = $-26.52 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Explanation

This is a more accurate valuation of companies' operation because it consider the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt).

Nivalis Therapeutics Inc's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2016 is calculated as:

Earnings Yield (Joel Greenblatt) (Q: Mar. 2016 )=EBIT (TTM)/Enterprise Value (Q: Mar. 2016 )
=-26.517/-15.7438
=168.43 %

Nivalis Therapeutics Inc's Enterprise Value for the quarter that ended in Mar. 2016 was $-15.74 Mil.
Nivalis Therapeutics Inc's Earnings Before Interest and Taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2016 was -5.852 (Jun. 2015 ) + -6.101 (Sep. 2015 ) + -6.63 (Dec. 2015 ) + -7.934 (Mar. 2016 ) = $-26.52 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.


Related Terms

Enterprise Value, Earnings Yield (Joel Greenblatt), Earnings Before Interest and Taxes (EBIT)


Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.

Nivalis Therapeutics Inc Annual Data

Dec12Dec13Dec14Dec15
ev2ebit 0.000.000.000.000.000.000.000.000.00-1.42

Nivalis Therapeutics Inc Quarterly Data

Dec13Mar14Jun14Sep14Dec14Mar15Jun15Sep15Dec15Mar16
ev2ebit 0.000.000.000.000.000.00-6.31-5.45-1.420.59
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK